Natriuretic Peptides for Heart Failure Diagnosis and Risk Stratification
Use BNP or NT-proBNP as the primary peptide biomarkers for diagnosing heart failure and stratifying risk, with specific cutoff values that vary by clinical context (acute vs. chronic), age, and comorbidities. 1, 2
Diagnostic Cutoffs by Clinical Setting
Acute Heart Failure (Emergency Department)
For patients presenting with acute dyspnea, NT-proBNP is preferred over BNP due to more established age-adjusted thresholds 2:
NT-proBNP thresholds to diagnose acute HF:
- Age <50 years: >450 pg/ml
- Age 50-75 years: >900 pg/ml
- Age >75 years: >1,800 pg/ml
To exclude acute HF: BNP <100 pg/ml or NT-proBNP <300 pg/ml 1
Chronic Heart Failure
To exclude chronic HF: BNP <35 pg/ml or NT-proBNP <125 pg/ml 1
For risk stratification in chronic HFrEF trials: BNP ≥150 pg/ml or NT-proBNP ≥600 pg/ml 1
For risk stratification in chronic HFpEF trials: BNP ≥100 pg/ml or NT-proBNP ≥360 pg/ml 1
Critical Adjustments for Comorbidities
Obesity (BMI ≥30 kg/m²)
Lower all thresholds by 20-30% because natriuretic peptides are falsely reduced in obese patients due to increased clearance by adipocytes and reduced production 1. This is particularly important in HFpEF where obesity prevalence is high.
Atrial Fibrillation
Raise all thresholds by 20-30% because AF independently elevates natriuretic peptides through atrial stretch 1.
Renal Failure (eGFR <60 mL/min/1.73 m²)
Use higher decision limits as natriuretic peptides are cleared renally and accumulate with kidney dysfunction 2. The exact adjustment is not standardized but clinical judgment should account for significantly elevated baseline values.
Black Patients
Lower thresholds by 20-30% to avoid exclusion from appropriate diagnosis and treatment, as this population tends to have lower baseline natriuretic peptide levels 1.
Elderly Patients (>75 years)
Raise thresholds by 20-30% as natriuretic peptides physiologically increase with age 1.
Medication Considerations
Neprilysin Inhibitors (Sacubitril/Valsartan)
- Avoid using BNP for monitoring treatment response to neprilysin inhibitors, as BNP is degraded by neprilysin and levels will rise artifactually during therapy 1
- NT-proBNP requires no adjustment and remains reliable for monitoring, as it is not a neprilysin substrate 1
- BNP can still be used for initial diagnosis and risk stratification before starting therapy
Prognostic Use
Acute Pulmonary Embolism
Natriuretic peptides identify high-risk PE patients 2:
- NT-proBNP <500-1,000 pg/ml predicts better clinical course
- BNP <50-90 pg/ml identifies low-risk patients
- BNP >500 pg/ml identifies high-risk patients requiring echocardiography
Acute Coronary Syndrome
- BNP >80 pg/ml or NT-proBNP >1,170 pg/ml (men) or >2,150 pg/ml (women) identifies high-risk ACS patients 2
- Combination with troponin improves risk stratification
Predischarge Risk Assessment
- NT-proBNP >137 pg/ml at discharge predicts poor prognosis 2
- ≥30% reduction in BNP during hospitalization is associated with improved survival 2
Common Pitfalls to Avoid
- Do not use a single universal cutoff across all ages and clinical contexts—this leads to misdiagnosis in elderly and young patients
- Do not ignore obesity—failure to adjust downward leads to missed HF diagnoses in obese patients, who represent a large proportion of HFpEF
- Do not use BNP to assess response to sacubitril/valsartan—it will rise paradoxically despite clinical improvement
- Do not rely solely on natriuretic peptides—integrate with clinical presentation, LVEF, and other comorbidities for complete risk assessment 1
Note: The evidence provided regarding other peptides (saxagliptin for disorders of consciousness 3, epithalamin for aging 4, GLP-1 agonists for diabetes 5) addresses entirely different clinical questions unrelated to the cardiovascular diagnostic context where natriuretic peptides are the established standard of care.